Akeso

Breakthrough Immunotherapies And Aging Trends Will Revitalize Global Oncology

AnalystHighTarget

Not Invested

Community Contributor

Published

20 Jun 25

AnalystHighTarget's Fair Value

HK$226.16

41.3% undervalued

10 Sep

HK$132.70

96.9%

2.3%

96.9%

2.3%

You can edit this narrative until Jun 20 9:13 PM. Then, changes will post as Updates.

Author's Valuation

HK$226.16

41.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

HK$226.16

41.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

34.35%

Biotech revenue growth rate

8.19%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.89%

Calculation

CN¥6.25b

Earnings '28

36.89x

PE Ratio '28

CN¥230.56b

Market Cap '28

CN¥230.56b

Market Cap '28

888.03m

No. shares '28

CN¥259.62

Share Price '28

CN¥259.62 Share Price '28

Discounted to 2025 @ 6.89% p.a.

CN¥212.59

Fair Value '25

CN¥212.59 Fair Value '25

Converted to HKD @ 1.0938 CNY/HKD Exchange Rate

HK$232.52

Fair Value '25